Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Get your Portfolio automatically emailed to you up to 4 times a day with Barchart Premier. FREE 30 Day Trial
Stocks | Futures | Watchlist | News | More
or
Faster, Cleaner, Better.

Vistagen Therapeutics Inc (VTGN)

Vistagen Therapeutics Inc (VTGN)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 26,782
  • Shares Outstanding, K 39,495
  • Annual Sales, $ 490 K
  • Annual Income, $ -51,420 K
  • EBIT $ -65 M
  • EBITDA $ -66 M
  • 60-Month Beta 0.56
  • Price/Sales 53.89
  • Price/Cash Flow N/A
  • Price/Book 0.34
  • Price/Earnings ttm 0.00
  • Earnings Per Share ttm -1.90
  • Most Recent Earnings $-0.54 on 11/13/25
  • Next Earnings Date 02/12/26
  • Annual Dividend & Yield 0.00 (0.00%)
  • Most Recent Dividend N/A on N/A
  • Sector Medical
  • INDUSTRY GROUPING Medical - Biomedical

Options Overview Details

View History
  • Implied Volatility 203.10% (+26.94%)
  • Historical Volatility 476.34%
  • IV Percentile 76%
  • IV Rank 29.10%
  • IV High 518.95% on 11/20/25
  • IV Low 73.45% on 01/15/25
  • Expected Move (DTE 16) 0.2465 (36.35%)
  • Put/Call Vol Ratio 0.19
  • Today's Volume 223
  • Volume Avg (30-Day) 4,726
  • Put/Call OI Ratio 0.32
  • Today's Open Interest 49,886
  • Open Int (30-Day) 63,798
  • Expected Range 0.4316 to 0.9246

Analyst Rating / Earnings Estimates

Current Rating
See More
Hold
Based on 5 analysts offering recommendations.
Earnings Estimates - Current Qtr 12/31/25
See More
  • Average Estimate -0.50
  • Number of Estimates 2
  • High Estimate -0.49
  • Low Estimate -0.52
  • Prior Year -0.46
  • Growth Rate Est. (year over year) -8.70%

Price Performance

See More
Period Period Low Period High Performance
1-Month
0.6537 +3.73%
on 12/29/25
4.9090 -86.19%
on 12/01/25
-4.2219 (-86.16%)
since 11/28/25
3-Month
0.6537 +3.73%
on 12/29/25
5.1400 -86.81%
on 11/24/25
-2.8719 (-80.90%)
since 09/30/25
52-Week
0.6537 +3.73%
on 12/29/25
5.1400 -86.81%
on 11/24/25
-2.1319 (-75.87%)
since 12/30/24

Most Recent Stories

More News
Vistagen Announces Topline Results from PALISADE-3 Phase 3 Public Speaking Challenge Study of Fasedienol for the Acute Treatment of Social Anxiety Disorder

Study did not demonstrate statistically significant improvement on primary endpoint of reduction in anxiety as measured by SUDS scores compared to placebo Favorable safety...

VTGN : 0.6781 (+2.26%)
Vistagen Appoints Nick Tressler as Chief Financial Officer

Vistagen (Nasdaq: VTGN), a late clinical-stage biopharmaceutical company pioneering neuroscience with nose-to-brain neurocircuitry to develop and commercialize a new class of intranasal product candidates...

SENS : 5.51 (-2.82%)
AZN : 92.51 (-0.01%)
VTGN : 0.6781 (+2.26%)
Vistagen Reports Findings on PH80’s Brain and Autonomic Effects in Women with Menopausal Hot Flashes at The Menopause Society 2025 Annual Meeting

Research supports the product candidate’s non-hormonal, non-systemic, rapidly-acting effects on autonomic biomarkers

VTGN : 0.6781 (+2.26%)
Vistagen Reports Fiscal Year 2026 Second Quarter Financial Results and Provides Corporate Update

PALISADE-3 Phase 3 Public Speaking Challenge Study of Fasedienol for the Acute Treatment of Social Anxiety Disorder is Complete; Topline results expected by calendar year end

VTGN : 0.6781 (+2.26%)
Vistagen to Report Fiscal Year 2026 Second Quarter Results and Host Corporate Update Conference Call on November 13, 2025

Vistagen (Nasdaq: VTGN), a late clinical-stage biopharmaceutical company pioneering neuroscience with nose-to-brain neurocircuitry to develop and commercialize a new class of intranasal product candidates...

VTGN : 0.6781 (+2.26%)
Vistagen to Participate in Stifel Healthcare Conference 2025

Vistagen (Nasdaq: VTGN), a late clinical-stage biopharmaceutical company pioneering neuroscience with nose-to-brain neurocircuitry to develop and commercialize a new class of intranasal product candidates...

VTGN : 0.6781 (+2.26%)
Vistagen Completes PALISADE-3 Phase 3 Public Speaking Challenge Study for the Acute Treatment of Social Anxiety Disorder

Topline results for the trial are expected by year end

VTGN : 0.6781 (+2.26%)
Vistagen Appoints Paul Edick to its Board of Directors

Mr. Edick brings extensive industry experience across product development, commercial launch, and growth strategy

VTGN : 0.6781 (+2.26%)
Vistagen to Present at The Menopause Society 2025 Annual Meeting

Posters Highlight New Insights into PH80’s Effects on Brain and Autonomic Activity

VTGN : 0.6781 (+2.26%)
Janus Henderson Just Took a 13.6% Stake in Vistagen. Should You Buy VTGN Stock Now?

The noted firm’s investment acts as a vote of confidence for this niche biotech company.

VTGN : 0.6781 (+2.26%)

Business Summary

VistaGen Therapeutics, Inc. is a biotechnology company. It is engaged in developing and commercializing product candidates for diseases and disorders involving the central nervous system. The company's lead product candidate consists of AV-101, is an orally available prodrug candidate in Phase II development,...

See More

Key Turning Points

3rd Resistance Point 0.7271
2nd Resistance Point 0.7085
1st Resistance Point 0.6933
Last Price 0.6781
1st Support Level 0.6595
2nd Support Level 0.6409
3rd Support Level 0.6257

See More

52-Week High 5.1400
Fibonacci 61.8% 3.4262
Fibonacci 50% 2.8968
Fibonacci 38.2% 2.3675
Last Price 0.6781
52-Week Low 0.6537

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.
Free Barchart Webinar